

Typhocon™

Purified Typhoid Conjugate (Vi-DT) Vaccine INN

Presentation

Each 0.5 ml contains: Purified Typhoid Conjugate (Vi-DT) Vaccine INN containing purified Vi-capsular polysaccharide of *Salmonella typhi* 25 mcg conjugated to diphtheria toxoid.

Description

Typhocon is a clear to slightly turbid liquid containing purified Typhoid Conjugate Bulk Antigen: 25 mcg (25 mcg of Vi polysaccharide of *Salmonella typhi* Ty2 conjugated to diphtheria toxoid) This is T-cell dependent vaccine which induces Vi antibodies that neutralize Vi antigen unlike T-cell independent plain Vi polysaccharide vaccines.

Indications and uses

Typhocon is indicated for active immunization against typhoid fever for infants of ≥6 months of age or older and adults upto 45 years. Selective immunization with typhoid vaccine is recommended for the following:

- Travelers to high endemic areas
- Household contact of carriers
- Healthcare personnel
- Police, armed forces and such other regimented personnel
- Laboratory workers who work with *Salmonella typhi*

Dosage and administration

Administration

The recommended dose of vaccine 0.5 ml is to administered intramuscularly.

Doses

The immunizing dose for adults, children and infants of ≥6 months age or older and adults upto 45 years is single dose of 0.5 ml.

Revaccination

Booster dose may be given after 3 years

Method of administration

Typhoid Vi conjugate vaccine should be given intramuscularly in the deltoid or the vastus lateralis of subjects. Typhoid Vi conjugate vaccine should not be injected into the gluteal area or areas where there may be a nerve trunk. Prevention becomes effective in 2 weeks after immunization.

Contra-indications

- Hypersensitivity to any constituent of the vaccine.
- In the event of fever or severe infection.

Precautions

- Do not administer intravenously, intradermally, or subcutaneously.
- Typhoid conjugate vaccine protects against typhoid fever caused by *Salmonella typhi* Ty2.
- Protection is not conferred against *Salmonella Paratyphi* and other non-typhoidal *Salmonellae*.
- Epinephrine injection (1:1000) must be immediately available in case of an acute anaphylactic reaction or any allergic reaction occurs due to any component of the vaccine. The vaccinee should remain under medical supervision for not less than 30 minutes after vaccination. Like all other vaccines, supervision and appropriate medical treatment should always be available to treat any anaphylactic reactions following immunization.

Co-administration

For concomitant or co-administration different injection sites and separate syringes should be used. Typhoid conjugate vaccine should not be mixed with any other vaccine or medicinal product, because interactions with other vaccines or medical products have not been established.

Use in specific populations

Pregnancy: Safety and effectiveness have not been established in pregnant women.

Lactation: Safety and effectiveness have not been established in nursing mothers.

Fertility: No fertility data available

Side effects

Systemic adverse effects

- Common: ≥ 1% and < 10%: Fever, headache, diarrhea, nausea, vomiting
- Uncommon: ≥ 0.1% and < 1%: Itching, fatigue, malaise, myalgia, muscle ache, lethargy, persistent crying, general ache, arthralgia, drowsiness, loss of appetite, chills, rash, gastroenteritis, increased hepatic enzyme, rhinitis, bronchitis, acute respiratory tract infection, upper respiratory tract infection, pharyngitis, nasopharyngitis.

Local adverse effects

- Very Common: ≥ 10%: Pain at injection site, redness, soreness
- Common: ≥ 1% and < 10%: Tenderness, swelling at the injection site.

Overdose

Not applicable.

Storage

- Keep out of the reach and sight of children
- Store at +2 °C to +8 °C. Transportation should also be at +2 °C to +8 °C
- Protect from light
- Do not freeze

Commercial Pack

Typhocon™ each box contains 1 pre-filled syringe of 0.5 ml Typhoid Conjugate Vaccine INN and 2 needles.